Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
- PMID: 40308026
- DOI: 10.1093/bjd/ljaf154
Nonsyndromic epidermal differentiation disorders: a new classification toward pathogenesis-based therapy
Abstract
Epidermal differentiation disorders (EDDs) encompass inherited conditions characterized by abnormal epidermal differentiation, including nonsyndromic and syndromic subtypes with more extensive cutaneous involvement or palmoplantar keratoderma. Nonsyndromic EDDs (nEDDs) are defined as disorders that primarily affect large areas of skin and adnexal structures without alterations in extracutaneous tissues resulting from the underlying genetic change. To facilitate the development of targeted therapies and to provide clinicians with clearer therapeutic guidance, we have developed a new nomenclature for EDDs that includes the causative altered gene and the nEDD subgroup designation, sometimes with a clinical or histological descriptor or acronym. Historically, many nEDDs have been named on the basis of phenotypic characteristics or associations that are now considered outdated or inappropriate. For example, the term 'harlequin ichthyosis' evokes potentially stigmatizing images. Similarly, the word 'ichthyosis' is derived from the Greek ichthys, meaning fish, and the Greek hystrix, meaning porcupine, further emphasizing the need to abandon derogatory terminology. As a result, the clinical relevance of the previous classification, which included eponymous and/or descriptive titles, has diminished. In the new, gene-based classification, old terms considered pejorative, such as ichthyosis, vulgaris, hystrix and harlequin have been eliminated and eponyms have been replaced. Among the 53 genetically distinct nEDDs are conditions formerly known as autosomal recessive congenital ichthyosis, erythrokeratodermia variabilis et progressiva, Hailey-Hailey disease and Darier-White disease. This review outlines the updated nomenclature and classifications of nEDDs, linked to detailed clinical descriptions and representative photographs to guide practitioners.
Plain language summary
Epidermal differentiation disorders (or ‘EDDs’ for short) are a group of inherited skin conditions. They affect the outermost layer of the skin, called the ‘epidermis’. The epidermis protects the body from things like germs and harmful substances. When the epidermis does not form properly, it can lead to skin problems like dryness, scaling and thickening. We have developed a new naming system for EDDs, based on the specific genes involved. The new system includes many diseases that used to be known by other names. We aim to make it easier for patients and doctors to understand the underlying causes of these conditions. There are 53 types of ‘non-syndromic’ EDDs (or ‘nEDDs’ for short). nEDDs affect only the skin and no other parts of the body. Some examples of nEDDs are ichthyosis (pronounced ‘ik-thee-oh-sis’), erythrokeratodermia variabilis et progressiva, Hailey–Hailey disease and Darier–White disease. These conditions were named based on their symptoms or abbreviations. The new classification uses the gene responsible for the disorder in the disease name. It will help patients understand their condition. It will also allow doctors to provide more targeted treatments. In the new classification, names based on individuals, offensive terms and outdated words have been removed. The new naming system for EDDs is based on the gene that causes the disease. It aims to support more effective treatments.
© The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists.
Conflict of interest statement
Conflicts of interest: A.G. holds stock in GSK, Novo Nordisk, Novartis, UCB and Sandoz; has been a paid consultant/advisory board member/speaker for LEO Pharma, Sanofi, Novartis, UCB, AbbVie, BMS, Pfizer and Almirall; has received grants from La Roche Posay and the LEO Foundation; and has been a patient advisor for the Pachyonychia Congenita (PC) Project. A.H. has provided consultancy/been on advisory boards for Boehringer Ingelheim and Kamari Pharma; has received research grants from Daiichi-Sankyo, Sixera Pharma, CureEB, EB Research Partnership, the PC Project and Association Ichtyose France (AIF); and has been a patient advisor for the PC Project. A.H.-M. has been an investigator for Mayne Pharma and Celgene; has been a consultant/on advisory boards for Sanofi, Viatris, Almirall, Galderma and L’Oréal; and has been a speaker for Sanofi, Viatris, L’Oréal, Leti Pharma and Beiersdorf. A.S.P. has been an investigator for AbbVie, Applied Pharma Research, Biomendics, Dermavant, Eli Lilly, Incyte, Janssen, Krystal, Regeneron, Timber and UCB; has been a consultant/on advisory boards for Abeona, Apogee, Arcutis, ASLAN, BioCryst, Boehringer Ingelheim, Castle Creek, Bristol Myers Squibb, Dermavant, Incyte, Krystal, LEO Pharma, L’Oréal, Mitsubishi Tanabe, MoonLake Immunotherapeutics, Procter and Gamble, Regeneron, Sanofi, Seanergy and UCB; has been on data safety monitoring boards (DSMBs) for AbbVie, Abeona and Galderma; and has been a patient advisor for the Foundation for Ichthyosis & Related Skin Types (FIRST; Chair, Medical and Scientific Advisory Board) and the International Pachyonychia Congenital Consortium. C.B. has been an investigator for Sanofi, Pfizer, AbbVie, Boehringer Ingelheim, Amryt, Reacell, Krystal, Novartis, Pierre Fabre and Timber Pharmaceuticals; has been a consultant/on advisory boards for Sanofi, AbbVie, Boehringer Ingelheim and Amryt (Chiesi); and has been a speaker for Boehringer Ingelheim, Amryt (Chiesi), Krystal and Alexion. C.G.T. received an honorarium for providing support for this paper. E.A.O.T. has been an investigator for Kamari Pharma and Palvella Therapeutics; a consultant/on advisory boards for Kamari Pharma, Palvella Therapeutics and Azitra; has received research grants from Unilever, the LEO Foundation and Kamari Pharma (all money paid to university/hospital); and has been a patient advisor for the PC Project and Ichthyosis Support Group (ISG). E.S. has been a consultant/on advisory boards for Kamari Pharma, Amryt and SolGel (all money paid to hospital); and has been a patient advisor for the PC Project. G.T. received a grant from the UFFI Society (United for fighting Ichthyoses) relevant to this paper. J.M.-H. has been an investigator for Mayne and Timber Pharmaceuticals. J.S. is Executive Director of the PC Project. J.M.C.T. has been an investigator for Castle Creek, LEO Pharma, Novartis, Palvella Therapeutics, Pfizer, Regeneron, Syneos, Timber Pharmaceuticals and Twi Biotech; has been a consultant/on advisory boards for Abeona, AFT, Amryt, AUCTA, Biocryst, Bridge Bio, Castle Creek, Coterie, GLG, Guide Point, Innova, Kamari, KrystalBio, LEO Pharma, Lifemax Menlo Therapeutics, Mitsubishi, NobelPharm, Novartis, Palvella Therapeutics, Pfizer, Pierre Fabre, Regeneron, Syneos, Timber Pharmaceuticals, Topicals and Twi Biotech; has been a patient advisor for the Gorlin Syndrome Alliance, the TSC Alliance, FIRST and the PC Project; and has received royalties from GeneReview, UpToDate and Springer Publishing. K.C. has been an investigator for AbbVie, Boehringer Ingelheim and Regeneron; has been a consultant/on advisory boards for Mitsubishi Tanabe, Biocryst, Kamari Pharma, Resvita and Timber Pharmaceuticals; and has been a patient advisor for FIRST. M.A. has been a paid advisory board member/speaker for Boehringer Ingelheim, Maruho Co., Ltd. and Sanofi K.K.; and has received research grants from Boehringer Ingelheim, Novartis Pharma K.K. and Maruho Co., Ltd. M.A.-E. is an employee of ISG. M.S. has been an investigator for AbbVie, Clinuvel, Incyte and MSD; has received research grants from the Austrian Science Fund, the European Union, EI Cure and the PC Project (all money to university/hospital); has been on a DSMB paid for by Biontech; and has been a patient advisor for EI Cure and FIRST. A.I.-Y., J.F. and K.M. declare no conflicts of interest.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials